Thromboembolic Diseases Background information for medical media outside the US only This selection gives an overview on background material for Thromboembolic Diseases available on the Boehringer Ingelheim corporate website.

News Release

• 11 November 2008Longest follow-up period for any new oral anticoagulant explores Pradaxa® (dabigatran etexilate) for stroke prevention in atrial fibrillation (AF)
• 24 September 2008Positive UK health technology appraisal for novel oral anticoagulant Pradaxa® (dabigatran etexilate)
• 09 June 2008Boehringer Ingelheim announces first positive health technology assessments for novel oral anticoagulant Pradaxa® (dabigatran etexilate)
• 27 March 2008Novel oral anticoagulant Pradaxa® (dabigatran etexilate) approved by the European Commission (for medical media, outside the US only)
• 17 January 2008Boehringer Ingelheim announces enrolment completion of the largest atrial fibrillation outcomes trial - The RE-LY® Study
• news release archive

Documents

• Fact sheet: Dabigatran Etexilate - March 2008 - PDF (63 KB)
• Fact sheet: Dabigatran Etexilate - A Breakthrough in Anticoagulation - March 2008 - PDF (55 KB)
• Backgrounder: Boehringer Ingelheim at a glance - March 2008 - PDF (2,2 MB)
• Backgrounder: Dabigatran Etexilate - A brief history - March 2008 - PDF (35 KB)
• Backgrounder: Venous Thromboembolism (VTE) - March 2008 - PDF (51 KB)
• Glossary: Thromboembolic Diseases - March 2008 - PDF (42 KB)